GSK PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,780 GBX | +0.39% |
|
+3.01% | +22.78% |
| 05-08 | Gsk plc Announces Board Committee Changes | CI |
| 05-08 | GSK : Receives a Buy rating from Bernstein | ZD |
Presenter SpeechIain Mackay (Executives)Good morning and good afternoon. I'm Iain Mackay, CFO ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.8
GBP
Average target price
20.24
GBP
Spread / Average Target
+13.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.78% | 90.35B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +8.62% | 165B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- Transcript : GlaxoSmithKline plc - Special Call